Conditions: Lung Cancer Breast Cancer
Keywords: lung cancer breast cancer
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 14
Healthy volunteers: no

Brief summary:
The purpose of this study is to assess the long-term safety profile and the secondary objective to estimate clinical benefit of ZD1839 (gefitinib).

Detailed description:

Arms:
arm 1: ZD1839 at a daily dose of 250 mg or 500 mg depending on final dose in parent trial

Interventions: intervention 1: Gefitinib
Intervention descriptions: intervention 1: ZD1839 at a daily dose of 250 mg or 500 mg depending on final dose in parent trial

Protocol document: